UroGen Pharma Ltd. (URGN) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $23.37 (-1.93%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 9, 2026 | Amin Makarem | Jefferies | $40.00 | +71.2% |
| Jun 13, 2025 | Paul Choi | Goldman Sachs | $16.00 | -31.5% |
| Jun 13, 2025 | Leland Gershell | Oppenheimer | $31.00 | +32.6% |
| Oct 14, 2024 | Jason Kolbert | EF Hutton | $25.00 | +7.0% |
| Jun 14, 2024 | Stephen Richardson | Evercore ISI | $46.00 | +96.8% |
| Jun 14, 2024 | Leland Gershell | Oppenheimer | $40.00 | +71.2% |
| Jun 14, 2024 | Raghuram Selvaraju | H.C. Wainwright | $60.00 | +156.7% |
| Jun 14, 2024 | Paul Choi | Goldman Sachs | $22.00 | -5.9% |
| May 14, 2024 | Leland Gershell | Oppenheimer | $32.00 | +36.9% |
| Mar 15, 2024 | Leland Gershell | Oppenheimer | $34.00 | +45.5% |
Top Analysts Covering URGN
URGN vs Sector & Market
| Metric | URGN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 4 | 8 | 18 |
| Target Upside | +71.2% | +1150.2% | +14.9% |
| P/E Ratio | -7.74 | 6.88 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $224M | $248M | $272M | 7 |
| 2027-03-31 | $94M | $104M | $123M | 3 |
| 2027-06-30 | $103M | $115M | $136M | 3 |
| 2027-09-30 | $112M | $125M | $147M | 3 |
| 2027-12-31 | $122M | $135M | $160M | 3 |
| 2028-03-31 | $129M | $143M | $170M | 2 |
| 2028-06-30 | $134M | $149M | $177M | 2 |
| 2028-09-30 | $134M | $149M | $177M | 2 |
| 2028-12-31 | $140M | $155M | $184M | 2 |
| 2029-12-31 | $656M | $747M | $886M | 3 |
| 2030-12-31 | $830M | $946M | $1.12B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.70 | $-1.06 | $-0.21 | 7 |
| 2027-03-31 | $0.16 | $0.18 | $0.22 | 2 |
| 2027-06-30 | $0.27 | $0.31 | $0.38 | 2 |
| 2027-09-30 | $0.38 | $0.43 | $0.54 | 2 |
| 2027-12-31 | $0.47 | $0.54 | $0.67 | 2 |
| 2028-03-31 | $0.68 | $0.78 | $0.97 | 3 |
| 2028-06-30 | $0.73 | $0.84 | $1.03 | 3 |
| 2028-09-30 | $0.70 | $0.81 | $1.00 | 3 |
| 2028-12-31 | $0.71 | $0.81 | $1.00 | 3 |
| 2029-12-31 | $4.06 | $4.82 | $5.99 | 4 |
| 2030-12-31 | $5.40 | $6.42 | $7.97 | 2 |
Frequently Asked Questions
What is the analyst consensus for URGN?
The consensus among 4 analysts covering UroGen Pharma Ltd. (URGN) is Buy with an average price target of $35.60.
What is the highest price target for URGN?
The highest price target for URGN is $60.00, set by Raghuram Selvaraju at H.C. Wainwright on 2024-06-14.
What is the lowest price target for URGN?
The lowest price target for URGN is $16.00, set by Paul Choi at Goldman Sachs on 2025-06-13.
How many analysts cover URGN?
4 analysts have issued ratings for UroGen Pharma Ltd. in the past 12 months.
Is URGN a buy or sell right now?
Based on 4 analyst ratings, URGN has a consensus rating of Buy (2.00/5) with a +71.2% upside to the consensus target of $35.60.
What are the earnings estimates for URGN?
Analysts estimate URGN will report EPS of $-1.06 for the period ending 2026-12-31, with revenue estimated at $248M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.